Neoadjuvant Nivolumab in Patients with High-risk Nonmetastatic Renal Cell Carcinoma

Michael A. Gorin, Hiten D. Patel, Steven P. Rowe, Noah M. Hahn, Hans J. Hammers, Alice Pons, Bruce J. Trock, Phillip M. Pierorazio, Thomas R. Nirschl, Daniela C. Salles, Julie E. Stein, Tamara L. Lotan, Janis M. Taube, Charles G. Drake, Mohamad E. Allaf

Research output: Contribution to journalArticlepeer-review

31 Scopus citations


Neoadjuvant immune checkpoint blockade represents a novel approach for potentially decreasing the risk of recurrence in patients with nonmetastatic renal cell carcinoma (RCC). In this early phase clincal tiral, we evaluated the safety and tolerability of neoadjuvant treatment with the programmed cell death protein 1 (PD-1) inhibitor nivolumab in patients with nonmetastatic high-risk RCC. Nonprimary endpoints included objective radiographic tumor response rate, immune-related pathologic response rate, quality of life alterations, and metastasis-free and overall survival. In total, 17 patients were enrolled in this study and underwent surgery without a delay after receiving three every-2-wk doses of neoadjuvant nivolumab. Adverse events (AEs) of any grade occurred in 14 (82.4%) patients, with two (11.8%) experiencing grade 3 events. Ten (58.8%) patients experienced an AE of any grade potentially attributable to nivolumab (all grade 1-2), and no grade 4-5 AEs occurred regardless of treatment attribution. The most common AEs were grade 1 fatigue (41.2%), grade 1 pruritis (29.4%), and grade 1 rash (29.4%). All evaluable patients had stable disease as per established radiographic criteria, with one (6.7%) demonstrating features of an immune-related pathologic response. Quality of life remained stable during treatment, with improvements relative to baseline noted at ≥6 mo postoperatively. Metastasis-free survival and overall survival were 85.1% and 100% at 2 yr, respectively. PATIENT SUMMARY: In this study, we evaluated the safety and tolerability of preoperative administration of three doses of the immune checkpoint inhibitor nivolumab in patients with clinically localized high-risk renal cell carcinoma. We demonstrated the safety of this approach and found that, although most patients will not experience a radiographic response to treatment, a subset may have features of an immune-related pathologic response.

Original languageEnglish (US)
Pages (from-to)113-117
Number of pages5
JournalEuropean Urology Oncology
Issue number1
StatePublished - Feb 1 2022


  • Clinical trial
  • Immunotherapy
  • Neoadjuvant therapy
  • Renal cell carcinoma

ASJC Scopus subject areas

  • General Medicine


Dive into the research topics of 'Neoadjuvant Nivolumab in Patients with High-risk Nonmetastatic Renal Cell Carcinoma'. Together they form a unique fingerprint.

Cite this